3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Unknown
44
Recruiting
36
Completed
27
Not yet recruiting
16
Active not recruiting
10
Withdrawn
7
Terminated
4
Enrolling by invitation
2
Suspended
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Thyroid Neoplasms
1
Liver Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Hepatocellular
1
Interventions
Specimen Handling
2
lenvatinib
1
fludarabine
1
Sorafenib
1
Nivolumab
1
Magnetic Resonance Spectroscopy
1
Leukapheresis
1
Folfox protocol
1
Ethiodized Oil
1
Cyclophosphamide
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Suspended
×
Carcinoma, Hepatocellular
×
lenvatinib
×
Clear all
NCT05033522
2025-10-23
ALIVE
Mirror Biologics, Inc.
Phase 2/3
Suspended
150 enrolled